Neumora Therapeutics Inc. has released a corporate presentation outlining its current pipeline and leadership team. The company is advancing a range of drug candidates targeting major health disorders, including metabolic, neurodegenerative, and neuropsychiatric diseases. Key programs in development include NMRA-215 and an undisclosed therapy for obesity, NMRA-511 for agitation in Alzheimer’s disease, NMRA-GCASE and NMRA-CK1δ for Parkinson’s disease and ALS, as well as treatments for major depressive disorder and schizophrenia. The leadership team features experienced executives across operations, scientific development, and strategy. The presentation also highlights Neumora’s focus on developing brain-penetrant therapies with the goal of addressing unmet needs in large patient populations. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.